Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome

References

• Jaffe E S, Harris N L, Vardiman J W, Stein H. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Ed. Lyon, France 2001; 63–70, IARC Press
   Google Scholar
• Alici S, Bavbek S E, Kaytan E. Prognostic factors in localized aggressive non-Hodgkin's lymphoma. American Journal of Clinical Oncology 2003; 26: 1–5
   PubMed Web of Science ®Google Scholar
• Stasi R, Zinzani L, Galieni P, Lauta V M, Damasio E, Dispensa E, et al. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. European Journal of Haematology 1995; 54: 9–17
   PubMed Web of Science ®Google Scholar
• Aydin F, Yilmaz M, Ozdemir F, Kavgaci H, Yavuz M N, Yavuz A A. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. American Journal of Clinical Oncology 2002; 25: 570–572
   PubMed Web of Science ®Google Scholar
• Kerbel R S. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. American Journal of Pathology 1992; 141: 519–524
   PubMed Web of Science ®Google Scholar
• Fiorentino D F, Bond M W, Mosmann T R. Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. Journal of Experimental Medicine 1989; 170: 2081–2095
   PubMed Web of Science ®Google Scholar
• Burdin N, Péronne C, Banchereau J, Rousset F. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. Journal of Experimental Medicine 1993; 177: 295–304
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Abrams J, Bennett B, Figdor C G, de Vries J E. IL-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. Journal of Experimental Medicine 1991; 174: 1209–1220
   PubMed Web of Science ®Google Scholar
• O'Garra A, Stapleton G, Dhar V, Pearce M, Schumacher J, Rugo H, et al. Production of cytokines by mouse B-cells: lymphomas and normal B-cells produce interleukin-10. International Immunnology 1990; 2: 821–832
   PubMed Web of Science ®Google Scholar
• Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu D H, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proceedings of the National Academy of Sciences USA 1992; 89: 18890
   Web of Science ®Google Scholar
• Fayad L, Keating M J, Reuben J M, O'Brien S, Lee B N, Lerner S, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotyping characteristics and outcome. Blood 2001; 97: 256–263
   PubMed Web of Science ®Google Scholar
• Van Snick J. Interleukin-6: an overview. Annual Reviews in Immunology 1990; 8: 253–278
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1–10
   PubMed Web of Science ®Google Scholar
• Voorzanger N, Touitou R, Garcia E, Delecluse H J, Rousset F, Joab I, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma and act as cooperative growth factors. Cancer Research 1996; 56: 5499–5505
   PubMed Web of Science ®Google Scholar
• Hodge S, Hodge G, Flower R, Han P. Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood. Scandinavian Journal of Immunology 2000; 51: 67–72
   PubMed Web of Science ®Google Scholar
• Nelms K, Keegan A D, Zamorano J Z, Ryan J J. The IL-4 receptor: signalling mechanisms and biologic functions. Annual Reviews in Immunology 1999; 17: 701–738
   PubMed Web of Science ®Google Scholar
• The non Hodgkin's lymphomas pathologic classification project. National Cancer Institute sponsored study of classifications of non Hodgkin's lymphomas. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Snedecor G W, Cochran W G. Statistical methods. 7^th ed. Iowa state University, Ames, IA 1980
   Google Scholar
• Altman D G. Practical statistics for medical research. 1^st ed. Chapman & Hall, London 1991
   Google Scholar
• Wilcoxon F. Individual comparions by ranking methods. Biometrics Bulletin 1945; 1: 80
   Google Scholar
• Cox D R. Regression model and life table (with discussion). Journal of the Royal Statistics Society 1972; 11: 34187
   Google Scholar
• Blay J -Y, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993; 82: 2169–2174
   PubMed Web of Science ®Google Scholar
• Preti H A, Cabanillas F, Talpaz M, Tucker S L, Seymour J F, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Annals of Internal Medicine 1997; 27: 186–194
   Google Scholar
• Stasi R, Zinzani P L, Galieni P, Lauta V M, Damasio E, Dispensa E, et al. Prognostic value of serum IL-10 and IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. British Journal of Hematology 1994; 88: 770–777
   PubMed Web of Science ®Google Scholar
• Cortes J, Talpaz M, Cabanillas F, Seymour J F, Kurzrock R. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1995; 85: 2516–2520
   PubMed Web of Science ®Google Scholar
• Seymour J, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. Journal of Clinical Oncology 1995; 13: 575–582
   PubMed Web of Science ®Google Scholar
• Kono N, Kanada Y, Yamamoto R, Chizuka A, Suguro M, Hamaki T, et al. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan. Leukemia & Lymphoma 2000; 37: 151–156
   PubMed Web of Science ®Google Scholar
• Niitsu N, Iijima K, Chizuka A. A high serum soluble interleikin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. European Journal of Haematology 2001; 66: 24–30
   PubMed Web of Science ®Google Scholar
• Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. Journal of Cancer Research & Clinical Oncology 2005; 13: 73–79
   Web of Science ®Google Scholar
• Perez Encinas M, Bello J L, Bendana A, Rabunal M J, Gonzalez S, Abuin I, et al. Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma. Medical Clinics (Barcelona) 1998; 111: 161–167
   PubMed Web of Science ®Google Scholar
• Kono N, Kanda Y, Yamamoto R, Chizuka A, Suguro M, Hamaki T, et al. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan. Leukemia & Lymphoma 2000; 37: 151–156
   PubMed Web of Science ®Google Scholar
• Niitsu N, Iijima K. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma. Leukemia Research 2002; 26: 241–248
   PubMed Web of Science ®Google Scholar
• Pedersen L M, Klausen T W, Davidsen U H, Johnsen H E. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Annals of Hematology 2005; 84: 510–516
   PubMed Web of Science ®Google Scholar